Cyclosporine Drugs Market Report 2026

The cyclosporine drugs market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.83 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increase in organ transplant procedures, established efficacy in immune suppression, rising prevalence of autoimmune diseases, long-standing clinical usage, availability of generic formulations.

The cyclosporine drugs market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growth in transplant patient population, expansion of ophthalmic treatment indications, development of improved drug delivery systems, increasing demand for personalized immunosuppressive therapy, advancements in formulation technologies. Major trends in the forecast period include growing use in organ transplant immunosuppression, increasing application in autoimmune disorders, rising demand for modified release formulations, expansion of ophthalmic cyclosporine products, increased focus on dose optimization and safety.

The increasing demand for organ transplantation is expected to drive the growth of the cyclosporine drugs market in the coming years. Organ transplantation is a medical procedure in which a failing or damaged organ is replaced with a healthy organ from another individual. The demand for organ transplantation is rising due to the growing prevalence of end-stage organ diseases, as improvements in medical diagnostics and treatments have extended patient lifespans, resulting in more individuals reaching a stage where organ replacement is necessary. Cyclosporine drugs play a critical role in organ transplantation by suppressing the immune system’s response to prevent rejection of the transplanted organ, protecting it from attack by the recipient’s immune cells. For instance, in January 2025, preliminary data from the Organ Procurement and Transplantation Network (OPTN), a US-based government health system managed by the Health Resources and Services Administration, indicated that the United States performed 48,149 organ transplants in 2024, marking a 3.3% increase from 2023. Therefore, the growing demand for organ transplantation is fueling the cyclosporine drugs market.

Major companies in the cyclosporine drugs market are focusing on developing advanced solutions, such as ophthalmic medications, to deliver targeted treatment directly to the eyes. Ophthalmic medications are specially formulated pharmaceutical products used to treat eye conditions, including infections, inflammation, and dry eye, typically available as drops, ointments, or gels. For instance, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for VEVYE, the first water-free and preservative-free 0.1% cyclosporine ophthalmic solution. Developed using Novaliq’s proprietary EyeSol technology, VEVYE offers an innovative approach to treating dry eye disease, demonstrating significant effectiveness within four weeks. Its water-free formulation improves drug stability, enhances patient comfort, and minimizes irritation, representing a notable advancement in ophthalmic drug delivery and providing precise targeting of ocular inflammation.

In October 2024, Novaliq GmbH, a Germany-based cyclosporine drug manufacturer, partnered with Laboratoires Théa to market ciclosporin eye drop solutions across Europe as well as select countries in the Middle East and North Africa. This collaboration highlights Novaliq’s commitment to delivering innovative treatments for patients. The upcoming launch of Vevizye will strengthen the portfolio of preservative-free therapies for dry eye, a condition that significantly impacts the quality of life for many individuals. Laboratoires Théa is a France-based pharmaceutical company.

Major companies operating in the cyclosporine drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Astellas Pharma Inc., Apotex Inc., Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Biocon Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Concord Biotech Limited, CKD Bio Corporation, ChemWerth Inc., Strides Pharma Science Limited, Fishfa Biogenics.

North America was the largest region in the cyclosporine drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cyclosporine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the cyclosporine drugs market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation excipients used in cyclosporine-based medications. These impacts have been most evident in branded and ophthalmic cyclosporine segments, particularly in North America and Europe where API sourcing is globally diversified. Asia-Pacific manufacturers have faced supply chain and pricing pressures due to trade dependencies. However, tariffs have supported domestic API production and local formulation manufacturing.

The cyclosporine drugs market research report is one of a series of new reports that provides cyclosporine drugs market statistics, including cyclosporine drugs industry global market size, regional shares, competitors with a cyclosporine drugs market share, detailed cyclosporine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine drugs industry. This cyclosporine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cyclosporine drugs are immunosuppressive medications primarily used to prevent organ rejection in transplant patients and to treat certain autoimmune disorders. They work by inhibiting T-lymphocyte activity, a type of white blood cell involved in immune responses, thereby reducing inflammation and excessive immune activity.

The main types of cyclosporine drugs include oral and parenteral forms. Oral cyclosporine is taken by mouth to suppress the immune system and is available in capsules, oral solutions, injectable forms, and topical preparations. It is used for organ transplantation, autoimmune disorders, ophthalmic conditions, and dermatological disorders. End users include hospitals, specialty clinics, homecare settings, and pharmaceutical retail outlets.

The cyclosporine drugs market consists of sales of therapeutic drug monitoring kits, supportive care medications and cyclosporine active pharmaceutical ingredient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.